BioXcel Therapeutics Pioneers New Public Offering
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has initiated a new chapter as they announce their underwritten public offering of shares. This biopharmaceutical company is at the forefront of integrating artificial intelligence to develop innovative treatments in neuroscience and immuno-oncology. The offering includes shares of Common Stock, valued at $0.001 each, along with warrants, providing various investment options for interested stakeholders.
Details on the Public Offering
Canaccord Genuity assumes the role of sole book-running manager for this public offering. While the Company is optimistic about this venture, they acknowledge that the offering's completion depends on market conditions and other influencing factors. It is essential for investors to understand that the Company will be offering all the securities in this transaction.
Funding Future Trials and Corporate Goals
The proceeds from this offering are earmarked for several strategic purposes, including the funding of the SERENITY At-Home trial. Additionally, preparations will be underway for launching the TRANQUILITY In-Care trial. The Company’s financial strategy also covers essential working capital and overall corporate objectives, reflecting their commitment to growth and innovation.
Registration Process and Compliance
This offering is compliant with a shelf registration statement previously filed with the Securities and Exchange Commission (SEC). Filed on November 2, 2023, it became effective just days later on November 13, 2023. All necessary documentation for potential investors will be compiled, ensuring transparency through a written prospectus supplement that will accompany the offering.
Contact Information for Interested Parties
Investors and interested parties can seek further information about the offering directly from Canaccord Genuity LLC, located at One Post Office Square, Suite 3000, Boston, MA 02109. For queries related to the offering, interested parties may reach out via email to the syndicate department.
Corporate/Investor Contact Details
For any corporate or investor-related inquiries:
Erik Kopp
BioXcel Therapeutics
Phone: 1.203.494.7062
ekopp@bioxceltherapeutics.com
Media Contact Information
For media inquiries, the following contact is available:
David Schull
Russo Partners
Phone: 858-717-2310
David.Schull@russopartnersllc.com
Frequently Asked Questions
What type of offering is BioXcel Therapeutics executing?
BioXcel Therapeutics is executing an underwritten public offering of shares and warrants related to its common stock.
What will the proceeds from the offering fund?
The funds raised will support the SERENITY At-Home trial, the upcoming TRANQUILITY In-Care trial, and general corporate purposes.
Who is managing the public offering?
Canaccord Genuity is serving as the sole book-running manager for the offering.
Where can the offering documents be accessed?
Prospective investors can find the preliminary prospectus supplements on the SEC's website.
How can investors contact BioXcel Therapeutics for inquiries?
Investors can email Erik Kopp at ekopp@bioxceltherapeutics.com for any inquiries related to the company or the offering.
